Osimertinib in UntreatedEGFR-Mutated Advanced Non–Small-Cell Lung Cancer
Work
Year: 2017
Type: article
Abstract: Osimertinib is an oral, third-generation, irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that selectively inhibits both EGFR-TKI–sensitizing and EGFR T790M resistan... more
Source: New England Journal of Medicine
Authors Jean‐Charles Soria, Yuichiro Ohe, Johan Vansteenkiste, Thanyanan Reungwetwattana, Busyamas Chewaskulyong +19 more
Institutions Institut Gustave Roussy, National Cancer Center, KU Leuven, Ramathibodi Hospital, Mahidol University +23 more
Cites: 33
Cited by: 4,190
Related to: 10
FWCI: 317.5
Citation percentile (by year/subfield): 100
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Sustainable Development Goal Good health and well-being
Open Access status: bronze